FDA Accepts BLA for Afami-Cel for Priority Review as Treatment of Advanced Synovial Sarcoma

Afami-cel had engineered t-cell receptor T-cells target MAGE-A4+ tumors, which are highly expressed in synovial sarcoma with HLA-A*02.

Related Keywords

Dublin ,Ireland ,Dennis Williams ,Connective Tissue Oncology Society ,Eastern Cooperative Oncology Group ,Stage Development At Adaptimmune Therapeutics ,Adaptimmune Therapeutics ,Prescription Drug User Fee Act ,Late Stage Development ,Tissue Oncology Society ,Subjects With Advanced Synovial Sarcoma ,Round Cell ,Completion Date ,